Quality Control Laboratory Assistant
About the job
- A Federal Certificate of Capacity or Maturity with knowledge of Chemistry and/or Biology.
- One to two years of work experience in a Good Manufacturing Practice (GMP) environment.
- Good knowledge and interpretation of current Good Manufacturing Practice (cGMP) and regulations applicable to the Quality Control environment.
- Good writing skills.
- Good knowledge of English and French.
- Knowledge of common office software.
- Participate in inventory management and ordering of test-related supplies required for release of raw and packaging materials, final product, stability samples, and in-process control testing.
- Ensure laboratory environmental, health, and safety requirements are met by following procedures and rules and immediately reporting incidents and near misses to management and/or the environmental, health, and safety representative.
- Manage chemical reagents, including ordering and inventory.
- Perform dedicated analytical testing, including infrared spectroscopy, pH, conductivity, total organic carbon, titration, and weighing.
- Perform basic laboratory work, including buffer preparation, growth promotion testing, waste disposal management, washing laboratory dishes, and cleaning laboratories.
- Support management of consumable supplies.
- Support equipment maintenance and calibration and maintain relationships with suppliers.
- Perform Quality Control laboratory archiving activities.
- Write specific standard operating procedures within the assigned field of activity.
- Create and/or verify Good Manufacturing Practice documents.
- Support selection, purchase, and commissioning of new reagents and consumables.
- Act as a subject matter expert for defined areas.
- Complete assigned special tasks and project work.
- Perform other job-related duties as requested by management.
About the company
What WuXi AppTec does: It provides a global, integrated open-access platform for contract research, development, and manufacturing services (CRDMO) to the pharmaceutical, biotechnology, and medical device industries. How its products work: Clients access a broad portfolio of capabilities—laboratory testing, process development, and manufacturing—across the full product lifecycle, from discovery and preclinical work to clinical and commercial production, often supported by strategic acquisitions to extend reach. How it differs from competitors: It combines extensive geographic reach with a wide, end-to-end service portfolio in one platform, rather than focusing on a narrow stage or region. What its goal is: To help innovators bring new medicines and healthcare products to market faster and with high quality.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Huangpu, China
Founded
2000
Get referred to WuXi AppTec
See people who can refer or advise you
Simplify's Take
What believers are saying
- WuXi AppTec raised 2026 revenue guidance to RMB 58.5-60.5 billion on August 3, 2026.
- H1 2026 revenue rose 38.9%, and backlog reached RMB 66.43 billion.
- Delaware starts Q4 2026 and Singapore starts 2027, expanding non-China manufacturing capacity.
What critics are saying
- On June 8, 2026, DoD added WuXi AppTec to the 1260H Chinese military list.
- Customers terminated, paused, and redirected programs within weeks after the June 2026 designation.
- If BIOSECURE targets WuXi in December 2026, U.S. business continuity faces existential damage.
What makes WuXi AppTec unique
- WuXi AppTec’s integrated CRDMO spans discovery, development, and manufacturing across 30-plus countries.
- Its 2026 capacity buildout covers Delaware, Singapore, Taixing, and Switzerland simultaneously.
- DMPK compound management serves thousands of clients with one-million-plus compound storage and traceability.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%WuXi AppTec says it runs one "One Global Quality System" across all its sites, rather than letting each location set local standards. From 2024 through the first half of 2026, it completed 2,008 quality audits and inspections by customers, regulators, and third parties, with no critical findings. The system aligns standards, procedures, and training across the network. Dirk Tormans, the company's head of quality assurance, said a qualification audit at an API facility can cut the time customers spend reviewing the same elements at a downstream drug-product site. At its Couvet, Switzerland site, the company took over a client's Phase 3 manufacturing and completed process transfer and scale-up within five months. The client submitted its New Drug Application on time, and Swissmedic, the US Food and Drug Administration (FDA), and Brazil's ANVISA later inspected the site without halting production.
WuXi AppTec reported strong first-half 2026 results and raised its full-year guidance. The Chinese pharmaceutical contract research, development, and manufacturing organisation posted H1 revenue of RMB 28.90 billion, up 38.9% year-on-year, with continuing operations revenue rising 48.0%. Adjusted non-IFRS net profit increased 83.2% to RMB 11.57 billion, whilst the gross profit margin expanded 9.4 percentage points to 53.9%. The company's backlog for continuing operations grew 25.2% to RMB 66.43 billion as of 30 June 2026. WuXi AppTec raised its 2026 total revenue target to RMB 58.5–60.5 billion, up from RMB 51.3–53.0 billion previously. The firm also increased its capital expenditure guidance to RMB 7.5–8.5 billion to support accelerated global capacity expansion. The company addressed its inclusion on the US Department of Defence's 1260H list, calling it erroneous and confirming legal action to protect stakeholder interests.
WuXi AppTec DMPK has launched an automated compound management platform serving thousands of pharmaceutical and biotechnology companies worldwide, with storage capacity exceeding one million compounds. The system provides full lifecycle management through digital operations, featuring automated robotic retrieval, real-time weighing data integration with high-precision balances, and automated preparation via Hamilton systems. The platform addresses three major challenges in drug metabolism and pharmacokinetics research: diverse container types, large compound libraries, and strict storage requirements. Key capabilities include real-time logistics tracking, image recognition-based automated picking, and high-density mobile storage delivering approximately fourfold capacity versus fixed-cabinet layouts. The system maintains tamper-proof audit logs and role-based access control whilst integrating with the Mosaic Compound Management System. WuXi AppTec DMPK offers flexible managed services covering sample receipt, secure storage, distribution, and disposal, aiming to reduce operational costs and accelerate research timelines.
WuXi AppTec is expanding its global manufacturing capabilities for emerging drug modalities including peptides, oligonucleotides and targeted protein degraders, according to Pharma Manufacturing. The company's WuXi TIDES platform, focused on oligonucleotides and peptides, is projected to achieve approximately 40% year-on-year revenue growth in 2026. The company's solid-phase peptide synthesis reactor volume exceeded 100,000 litres at end-2025 and is expected to reach 130,000 litres by end-2026. New production facilities are under construction in Taixing, China, scheduled for 2027 operation, and Singapore, planned for 2028. WuXi AppTec is investing in process technologies combining solid-phase and liquid-phase synthesis to improve scalability for complex molecules. The company is also developing integrated approaches for antibody-drug conjugates and targeted protein degraders, incorporating earlier-stage chemistry and biology integration.
WuXi AppTec has been added to the Pentagon's list of "Chinese military companies", escalating tensions between the pharmaceutical manufacturer and the US. The Department of Defence updated its Section 1260H list on 8 June, adding WuXi alongside other Chinese firms including BYD and Comac. The DoD claims WuXi has links to China's State Administration for Science, Technology and Industry for National Defence and the People's Liberation Army. WuXi strongly denied the designation, calling it "clearly a mistake" and stating it is not owned, controlled or affiliated with any Chinese military or government entity. The contract research and manufacturing organisation, which operates in over 30 countries, reported revenues of $1.83 billion in Q1 2026, up 39.4% year-over-year. WuXi was previously removed from the BIOSECURE Act in October 2025.